Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 3
1997 12
1998 11
1999 42
2000 30
2001 32
2002 52
2003 51
2004 55
2005 58
2006 69
2007 45
2008 44
2009 60
2010 42
2011 53
2012 46
2013 44
2014 51
2015 47
2016 45
2017 45
2018 36
2019 43
2020 57
2021 36
2022 47
2023 47
2024 58
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,154 results

Results by year

Filters applied: . Clear all
Page 1
Fexofenadine.
Markham A, Wagstaff AJ. Markham A, et al. Drugs. 1998 Feb;55(2):269-74; discussion 275-6. doi: 10.2165/00003495-199855020-00012. Drugs. 1998. PMID: 9506246 Review.
In a double-blind clinical trial, oral fexofenadine 120 or 180mg once daily controlled symptoms in patients with seasonal allergic rhinitis as effectively as cetirizine. Other double-blind clinical trials showed that fexofenadine 40 to 240mg twice daily was signific …
In a double-blind clinical trial, oral fexofenadine 120 or 180mg once daily controlled symptoms in patients with seasonal allergic rh …
Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.
Devillier P, Roche N, Faisy C. Devillier P, et al. Clin Pharmacokinet. 2008;47(4):217-30. doi: 10.2165/00003088-200847040-00001. Clin Pharmacokinet. 2008. PMID: 18336052 Review.
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levocetirizine - many pharmacological and clinical criteria must be considered. ...Desloratadine and fexofenadine do not impair cognitive …
When comparing the efficacy and safety profiles of the newest second-generation antihistamines - desloratadine, fexofenadine and levo …
Why fexofenadine is considered as a truly non-sedating antihistamine with no brain penetration: a systematic review.
Ansotegui IJ, Bousquet J, Canonica GW, Demoly P, Gómez RM, Meltzer EO, Murrieta-Aguttes M, Naclerio RM, Rosario Filho N, Scadding GK. Ansotegui IJ, et al. Curr Med Res Opin. 2024 Aug;40(8):1297-1309. doi: 10.1080/03007995.2024.2378172. Epub 2024 Jul 19. Curr Med Res Opin. 2024. PMID: 39028636 Free article. Review.
Results of brain H(1)-receptor occupancy (H(1)RO) obtained from PET showed no H(1)RO by fexofenadine, the receptor which is known to cause sedation of H(1) antihistamines. Most studies calculating PIR value as 0 showed fexofenadine to be a non-impairing oral antihis …
Results of brain H(1)-receptor occupancy (H(1)RO) obtained from PET showed no H(1)RO by fexofenadine, the receptor which is known to …
Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.
Mahatme MS, Dakhale GN, Tadke K, Hiware SK, Dudhgaonkar SD, Wankhede S. Mahatme MS, et al. Indian J Pharmacol. 2016 Nov-Dec;48(6):649-653. doi: 10.4103/0253-7613.194854. Indian J Pharmacol. 2016. PMID: 28066101 Free PMC article. Clinical Trial.

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was less in montelukast-levocetirizine group than in montelukast-fexofenadine group. CONCLUSION: The decrease in TNSS was more in montel

…

The mean change of TNSS, i.e., 9.46 was significant (P < 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was

…
An update on the clinical pharmacokinetics of fexofenadine enantiomers.
Akamine Y, Miura M. Akamine Y, et al. Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):429-434. doi: 10.1080/17425255.2018.1459565. Epub 2018 Apr 11. Expert Opin Drug Metab Toxicol. 2018. PMID: 29635947 Review.
Fexofenadine is administered as a racemic mixture of (R)- and (S)-enantiomers. The plasma concentrations of (R)-fexofenadine in humans are about 1.5-fold higher than those of the (S)-enantiomer. ...In vitro studies using OATP2B1 cRNA showed that (R)-fexofenadine …
Fexofenadine is administered as a racemic mixture of (R)- and (S)-enantiomers. The plasma concentrations of (R)-fexofenadine i …
[Determinants of the stereoselective pharmacokinetics of fexofenadine].
Akamine Y. Akamine Y. Yakugaku Zasshi. 2015;135(3):473-81. doi: 10.1248/yakushi.14-00218. Yakugaku Zasshi. 2015. PMID: 25759055 Free article. Review. Japanese.
This review focuses on the drug transporters contributing to the stereoselective pharmacokinetics of fexofenadine enantiomers in humans. Fexofenadine is administered clinically as a racemic mixture, and the plasma concentration of (R)-fexofenadine is about 1. …
This review focuses on the drug transporters contributing to the stereoselective pharmacokinetics of fexofenadine enantiomers in huma …
Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders.
Smith SM, Gums JG. Smith SM, et al. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22. doi: 10.1517/17425250903044967. Expert Opin Drug Metab Toxicol. 2009. PMID: 19545214 Review.
OBJECTIVE: To review the pharmacology, efficacy and safety of fexofenadine and the attributes differentiating it from other H(1)-antihistamines. METHODS: We performed a literature search in PubMed/MEDLINE (1966 - March 2009) using the keywords fexofenadine, antihist …
OBJECTIVE: To review the pharmacology, efficacy and safety of fexofenadine and the attributes differentiating it from other H(1)-anti …
Fexofenadine in pediatrics: oral tablet and suspension formulations.
Mansfield LE. Mansfield LE. Expert Opin Pharmacother. 2008 Feb;9(2):329-37. doi: 10.1517/14656566.9.2.329. Expert Opin Pharmacother. 2008. PMID: 18201155 Review.
The tablet formulation of the second-generation antihistamine fexofenadine has established efficacy and safety in both adults and children. To aid administration in young children, a new oral suspension formulation of fexofenadine has been developed, indicated for t …
The tablet formulation of the second-generation antihistamine fexofenadine has established efficacy and safety in both adults and chi …
Clinical pharmacokinetics of fexofenadine enantiomers.
Miura M, Uno T. Miura M, et al. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Expert Opin Drug Metab Toxicol. 2010. PMID: 19947891 Review.
This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports that co-administration of P-glycoprotein inhibitors has altered the stereoselective pharmacokinetics of fexofenadine enantiomers. ...T …
This article reviews the pharmacokinetic differences between fexofenadine enantiomers in humans and summarizes the previous reports t …
1,154 results